Follow the theme

Biotech trials and FDA decisions

Clinical trial readouts and FDA approval decisions: why one data release can double or halve a biotech stock in a single session.

For a drug developer with one or two late-stage products, a single trial result or regulatory decision can decide most of the company's value. Shares often gap up or down by double digits at the open, before anyone can react.

Our coverage explains what each readout actually showed, from the primary endpoint and hazard ratio to safety, and what comes next on the road to approval.